• 20 - Eyes to the Future

  • Oct 3 2024
  • Length: 5 mins
  • Podcast

20 - Eyes to the Future

  • Summary

  • La terza sessione presidenziale dell’ESMO ha avuto il suggestivo titolo “Eyes to the Future”. Ed effettivamente i trial presentati ci fanno intravvedere un futuro completamente diverso per l’oncologia. Da rimarcare due contributi italiani di grande importanza: ROME e NO-CUT.

    Bibliografia
    • Botticelli A, et al. The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy Abstract LBA7.
    • Amatu A, et al. Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial. Abstract 509O.
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about 20 - Eyes to the Future

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.